

Results of the 1st Quarter 2011/12

Mannheim, 28th June 2011



Reimund Pohl / Dr. Michael Majerus CEO / CFO



Disclaimer



© 2011 PHOENIX Pharmahandel GmbH & Co KG

This document has been prepared by PHOENIX Pharmahandel GmbH & Co KG (the "Company" and, together with its subsidiaries and affiliates, "PHOENIX") solely in connection with the release of the results of the 1st quarter 2011/12 and is being presented solely for informational purposes. No representation or warranty, express or implied, is or will be made in relation to, and no responsibility is or will be accepted by the Company or any of its respective affiliates, advisors or representatives (together, the "Parties") as to the accuracy or completeness of the information contained in this document, and nothing in this document shall be deemed to constitute such a representation or warranty. None of the Parties or their respective agents, directors, partners and employees accept any liability whatsoever (in negligence or otherwise) for any loss or damage howsoever arising from any use of this document or its contents or otherwise arising in connection therewith and no reliance should be placed on the information or statements made herein.

This document does not constitute or form part of and should not be construed as a recommendation, offer or invitation for the purchase or subscription of any securities of the Company or any subsidiary, and neither this document nor anything contained herein shall form the basis of, or be relied upon in connection with, any contract or commitment whatsoever.

The information contained in this presentation has not been subject to any independent audit or review. A portion of the information contained in this document, including all market data and trend information, is based on estimates or expectations of the Company, and there can be no assurance that these estimates or expectations are or will prove to be accurate. In addition, past performance of PHOENIX is not indicative of future performance. The future performance of PHOENIX will depend on numerous factors which are subject to uncertainty.

Certain statements contained in this presentation that are not statements of historical fact, including, without limitation, any statements preceded by, followed by or including the words "targets," "believes," "expects," "aims," "intends," "may," "anticipates," "would," "could" or similar expressions or the negative thereof, constitute forward-looking statements, notwithstanding that such statements are not specifically identified. In addition, certain statements may be contained in press releases, and in oral and written statements made by or with the approval of the Company that are not statements of historical fact and constitute forward-looking statements. Examples of forward-looking statements include, but are not limited to: (i) statements about future financial and operating results; (ii) statements of strategic objectives, business prospects, future financial condition, budgets, projected levels of production, projected costs and projected levels of revenues and profits of the Company or its management; (iii) statements of future economic performance; and (iv) statements of assumptions underlying such statements.

Forward-looking statements are not guarantees of future performance and involve certain risks, uncertainties and assumptions which are difficult to predict and outside of the control of the management of the Company. Therefore, actual outcomes and results may differ materially from what is expressed or forecasted in such forward-looking statements. You should not place undue reliance on these forward-looking statements. All subsequent written and oral forward-looking statements attributable to the Company or any person acting on its behalf are expressly qualified in their entirety by the cautionary statements referenced above. Forward-looking statements speak only as of the date on which such statements are made. The Company expressly disclaims any obligation or undertaking to disseminate any updates or revisions to any forward-looking statement to reflect events or circumstances after the date on which such statement is made, or to reflect the occurrence of unanticipated events.



Highlights of the 1st Quarter



Reimund Pohl CEO

Group Financials Q1 2011/12




Dr. Michael Majerus

Questions & Answers

Despite market pressure, PHOENIX maintains its growth path and significantly increases gross profit






- The balanced country portfolio ensures revenue growth despite pressure within our biggest markets, especially Germany, Italy and the United Kingdom
- Gross profit significantly improves as a result of margin-oriented sales policy, additional highermargin revenue in the fee-for-services business, and the increasing proportion of retail revenue

The year-over-year comparison shows positive developments of the results





- Within EBITDA, the increase on gross profit level compensates higher personnel costs and reduced income from other operating activities
- Next to the EBITDA contribution, profit before taxes is further increased versus previous year through the improved financial result

(mEUR)

Due to the first-time adoption of IAS
 19.93A, PY figures were made comparable

PHOENIX group's country portfolio allows for balancing PHOENIX group the pressure from both competition and market side





Positive developments Q1

- Q1 growth versus previous year underlines the resilience of PHOENIX's business model
- Strong and further growth in **Eastern Europe**
- Positive developments in Bosnia, Serbia and Macedonia
- Positive contributions from **Northern Europe**

Market pressure Q1

- High competition in France
- Negative effects from regulation (especially price reductions) in the United Kingdom and Italy
- New legislation governing the wholesalers' remuneration in **Germany** ("AMNOG")

AMNOG* changes the wholesalers' remuneration scheme in Germany





- The legislative authorities in Germany have clearly stated the political goal to save a total of 200 mEUR per year on the level of the pharmaceutical wholesalers
- This will be realized by changes in the remuneration scheme

Interim period 2011

- Continuation of the existing wholesalers' remuneration scheme:
 - Declining margin (15% to 6%); variable component only
 - Remuneration capped at 72.00 EUR
- For the interim period 2011, an overall wholesale rebate of 0.85% on all prescription drugs is imposed, generating savings of about 200 mEUR on the wholesalers' level

From 2012 onwards

- Flat margin scheme (3.15%); in addition fixed remuneration component of 0.70 EUR per article
- Wholesalers' remuneration capped at 38.50 EUR
- This adjustment of the remuneration scheme leads to similar savings in the amount of 200 mEUR on the level of the pharmaceutical wholesalers



PHOENIX strives to counterbalance the negative effects through various measures in the fields of sales and operations

In addition to organic growth, carefully selected acquisitions strengthen PHOENIX's market positions



Growth strategy

- PHOENIX's strategy is focused on profitable organic growth above the market average
- Profitable and financially sound add-on acquisitions may be pursued, but only within a pre-defined acquisition budget



- Acquisition of a 60% participation in Farcorpa Distribuzione S.r.I., a regional Italian wholesaler, per 15th of April
- With this acquisition, PHOENIX further strengthens its market-leading position and improves its geographical coverage in Italy



- Acquisition of three pharmacies and opening of four new shops to strengthen the retail position in selected countries
- Successful conclusion of the integration process of Lloyds
 Nederland BV in the context of our joint venture with Celesio AG in the Netherlands



Group Financials Q1 2011/12



Dr. Michael Majerus CFO

Q1 P&L reflects the positive profitability compared to previous year and the ending of restructuring costs



Profit & Loss (in mEUR)	Q1 * 2010/11	Q1 2011/12	Share of revenue	Delta in %
Revenue	5,381	5,397	100%	0.31%
Cost of goods sold Gross profit	-4,919 462	-4,912 485	-91.0% 9.0%	-0.14% 5.00%
Other Income Personnel expenses Other operative expenses Result from associates and other invest. EBITDA	43 -229 -150 4 130	37 -251 -135 0 136	0.7% -4.6% -2.5% 0.0% 2.5%	9.37% -9.82%
Interest from customers Costs of financial restructuring Factoring fees Adjusted EBITDA	5 4 2 141	6 0 1 144	0.1% 0.0% 0.0% 2.7%	27.77% -100.00% -9.53% 1.97%
Depreciation Financial result PBT	-22 -41 67	-23 -36 77	-0.4% -0.7% 1.4%	

New developments

- Despite the moderate revenue development, PHOENIX group achieved an increase in PBT
- Positive gross profit development compensates increase in personnel expenses, partially due to joint venture in the Netherlands

End of restructuring

 PHOENIX group is no longer burdened with restructuring costs which leads to improvements of EBITDA and also of the financial result

Due to the first-time adoption of IAS
 19.93A, PY figures were made comparable

PHOENIX group's optimized financial structure improves the financial result




Financial result (in mEUR)	Q1 2010/11	Q1 2011/12	Delta
Interest and other financial income	14.6	8.1	-6.5
Interest expenses and other financial expenses	-57.0	-45.5	11.5
Interest result	-42.4	-37.5	4.9
Net exchange effects & change in value of derivatives	1.6	3.2	1.6
Other financial result	-0.1	-1.5	-1.3
Financial result	-40.9	-35.7	5.2

New developments

- Reduction of interest income due to VEM loan repayment
- Reduced Net Debt lead to lower interest expenses

PHOENIX continues its committed path of strengthening its balance sheet






Due to the first-time adoption of IAS 19.93A, PY figures were made comparable. (Net effect in BS +22 mEUR)


Net Debt is slightly increased due to seasonal patterns, but still on low level compared to PY







- Net Debt reduction of 1.5 bnEUR compared to Q1 2010/11
- Significant optimization of debt structure



Q1 developments


 Net Debt increased by 0.2 mEUR in Q1 due to seasonal patterns

⁽mEUR)


Due to the first-time adoption of IAS 19.93A, PY figures were made comparable

Solid financial structure after refinancing provides meaningful financial flexibility










- Since end of last financial year PHOENIX negotiated extension of maturity for 0.4 bnEUR until end of 2015, prolongation of further 0.2 bnEUR currently under discussion
- With the extension of maturities beyond the maturity of the high yield bond banks signal their confidence in PHOENIX's credit worthiness

(mEUR)

The Q1 cash flow shows the expected swing due to seasonal working capital development





(in mEUR)	Q1 2010/11	Q1 2011/12
Change in WC	-283	-250
Free Cash Flow	-194	-202

Cash flow development

 As expected negative swing of working capital in Q1 alike to comparable previous period

(mEUR)

Summary: Development of key credit indicators





	01/31/2011	04/30/2011	Delta in %	
Equity (in mEUR)	1,761.1	1,793.6	1.8%	
Equity Ratio	23.2%	23.8%	2.5%	
Net Debt (in mEUR)	2,176.6	2,385.3	9.6%	
Gearing (Net debt/Equity)	1.24	1.33	7.6%	
	Q1 2010/11	Q1 2011/12	Delta in %	
EBITDA (in mEUR)	130.4	136.3	4.5%	
EBITDA-Margin	2.42%	2.52%	4.2%	
Adjusted EBITDA (in mEUR)	141.0	143.8	2.0%	
AdjEBITDA-Margin	2.62%	2.66%	1.7%	
Interest Coverage Ratio (BIT / Interest Expenses)	2.29	2.56	11.8%	

Lately, the PHOENIX bond has been influenced by Celesio's profit warning



PHOENIX PIB Finance BV EUR 506,150,000 9.625% guaranteed senior unsecured notes due 2014





Outlook



- The Q1 results of gross profit, EBITDA, and PBT are better than in the previous year
- The diversified country portfolio, the continuously optimized operational performance and optimized financing structure will allow PHOENIX group to realize its envisioned growth slightly above market average
- Despite the market and regulatory pressure in some countries and struggling competitors, PHOENIX group maintains its outlook for 2011/12

PHOENIX group with stringent financial policy



Deleveraging strategy

- Further deleveraging is integral part of PHOENIX's financial policy and is backed by its main shareholders
- Net Debt/EBITDA target of around 3.0x
- PHOENIX is confident to reach its leverage target in the next two years

No regular dividend payments

- In line with PHOENIX's deleveraging strategy, no regular dividend payments are planned for the next three years
- Loan and bond documentation also include dividend restrictions

Carefully managed acquisition activity

- PHOENIX's growth strategy is focused on above market organic growth
- Profitable and financially sound add-on acquisitions (mainly pharmacies) may also be pursued, but only within a predefined acquisition budget

PHOENIX group